Biopharma now runs on AI-generated research briefs, AI-synthesized competitive signals, and AI-drafted regulatory arguments. Almost none of it is adversarially validated before it reaches a decision-maker. The FDA doesn't catch it. The IC doesn't catch it. The regulatory VP doesn't catch it — because no one built the infrastructure to do that job.
Unverified AI-generated output is not intelligence. It is liability with the formatting of intelligence. When that output reaches a capital allocation decision, a clinical protocol, or an FDA submission, the exposure isn't theoretical — it's already in the room. Every organization reading this has already acted on it.
AimwellBio is the adversarial validation layer that sits between unverified AI-generated science and the decisions that depend on it. Not a dashboard. Not another SaaS subscription. The organizational immune system that the most serious biopharma operations have already deployed — and the one every other organization will wish they had first.
An unverified signal that arrives a week late is not intelligence — it's a postmortem. Cortex runs continuously because unverified AI-generated science doesn't pause for your quarterly review cycle. Neither does the exposure it creates.
When your VP of Regulatory leaves, everything they knew walks out the door. Cortex makes institutional knowledge permanent — surviving every transition, compounding with every decision.
The difference between a $200M decision and a $200M mistake is whether the AI-generated science behind it was ever challenged. Every Cortex output carries a 94% verdict confidence threshold, source-traced and hallucination-contained. Unchecked AI-generated intelligence is not a neutral input — it is an active liability.
$12–15B repricing inside the 2025–2026 CMS LCD cycle. 86 source-cited signals across PubMed, ClinicalTrials.gov, and SEC. 30 companies under continuous SCOUT monitoring. Refreshed live.
96 source-cited signals. 49 companies under continuous SCOUT monitoring. 18% Saudi diabetes prevalence — Vision 2030 procurement live. The platform that turns indication intelligence into adversarial verification.
146 source-cited signals including 30 SEER cancer-site stat facts. 50 companies under continuous SCOUT monitoring. Population epidemiology layered on adversarial verification — only oncology pipeline carries this.
1,710 source-cited signals across PubMed, ClinicalTrials.gov, FDA, and SEC. 50 companies under continuous SCOUT monitoring across the heart-failure, AFib, and cardiometabolic frontier. Sovereign GCC procurement live.
1,692 source-cited signals. 40 companies under continuous SCOUT monitoring across the CKD, ESRD, dialysis, and transplant frontier. The DKD intersection cross-tagged with the diabetes pipeline. Five sovereign anchors.
1,679 source-cited signals. 50 companies under continuous SCOUT monitoring across the GLP-1, GIP, and MASH frontier. Manufacturing-capacity leading indicators (Catalent, Halozyme). Five sovereign anchors.
Growth-stage biotechs that cannot afford to present an unverified AI-generated brief to their IC. Specialty pharma organizations where a missed regulatory signal costs more than the platform. Healthcare practitioners who need to know whether the clinical AI output they just used was ever challenged. Investment committees that have started asking, specifically, whether the science they are allocating capital against has been adversarially validated. They share one trait: they no longer treat unverified AI-generated science as a neutral input. They treat it as the risk it is.
AIMN:ATLAS is live — an interactive regulatory intelligence map tracking 65 companies and 11 regulatory agency heat zones across the global biopharma landscape. Built on verified signals, continuous monitoring, and persistent institutional memory. This is the infrastructure we describe. This is what works.
Explore AIMN:ATLAS →